GILD Price Prediction Next Week
Technical Analysis: GILD's stock shows strong bullish momentum based on technical indicators:
- RSI-14 at 75.90 indicates overbought conditions
- MACD (4.01) and Signal (2.88) are both positive with bullish crossover
- Stochastic RSI at 97.21 suggests strong upward momentum
- Price trading above all major moving averages (5,10,20,60,200-day)
Recent News Impact:
- Deutsche Bank upgraded GILD to Buy with PT raised to $120 from $80, citing strong HIV treatment franchise
- European Commission granted approval for seladelpar for liver disease treatment
- Q4 2024 results beat estimates with EPS of $1.90 vs $1.70 consensus
- Received high 90% rating from Validea's Earnings Yield Investor model
Price Prediction for Next Week: Based on Fibonacci levels and technical analysis:
- Support levels: $96.70, $92.82
- Resistance levels: $109.28, $113.17
- Current price: $109.58
Target price range for next week: $111-115
- Bullish case (60% probability): Break above $113.17 could push price to $119.46
- Bearish case (40% probability): Pullback to $109.28 support due to overbought conditions
Trading Recommendation: BUY
- Entry point: Current market price ($109.58)
- Stop loss: $106.50 (below 5-day SMA)
- Take profit: $115.00 (near upper Fibonacci R2)
Rationale:
- Strong technical momentum
- Positive analyst upgrades
- Recent regulatory approval in Europe
- Trading above all major moving averages
- Solid fundamental growth in HIV segment
GILD Similar Chart Price Prediction
The price of GILD is predicted to go up -10.83%, based on the high correlation periods with PI. The similarity of these two price pattern on the periods is 98.55%.
GILD
PI
Down: -10.83%Similarity: 98.55%
GILD Revenue Forecast
GILD EPS Forecast
GILD FAQs
What is bull’s view on GILD?
What is bear's view on GILD?
What is GILD revenue forecast for next quarter？
What is GILD eps forecast for next quarter？
GILD VS S&P500
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Guidelines that aim to improve diagnosis and treatment rates, and new prophylaxis use, provide strong tailwinds for growth in HIV.
Gilead's pipeline could begin to see more blockbuster launches, particularly if Trodelvy is able to see solid data expanding its approved indication.
GILD Analyst's Forecast
Brian Abrahams
RBC Capital
Hold
2025-02-12
Price Target
$84 → $90
Downside
-12.88%
RBC Capital analyst Brian Abrahams raised the firm's price target on Gilead to $90 from $84 and keeps a Sector Perform rating on the shares after its Q4 results and guidance. The company's FY25 is shaping up to be a more transitional year, with flattish revenue and earnings, but exiting FY24 with core franchise strength and with near-term headwinds likely to be transient, there is likely to be more concrete visibility towards medium-term growth, the analyst tells investors in a research note. RBC adds however that the Street already has high PrEP growth, HIV market conversion, and anito-cel uptake expectations.
Mohit Bansal
Wells Fargo
Buy
2025-02-12
Price Target
$105 → $120
Upside
+16.16%
Matthew Harrison
Morgan Stanley
Buy
2025-02-12
Price Target
$113 → $123
Upside
+19.06%
